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ABSTRACT Polyglutamine (polyQ) expansion leads to protein aggregation and neurodegeneration in Huntington’s disease and
eight other inherited neurological conditions. Expansion of the polyQ tract beyond a threshold of 37 glutamines leads to the
formation of toxic nuclear aggregates. This suggests that polyQ expansion causes a conformational changewithin the protein, the
nature of which is unclear. There is a trend in the disease proteins that the polyQ tract is located external to but not within a
structured domain. We have created a model polyQ protein in which the repeat location mimics the ﬂexible environment of the
polyQ tract in the disease proteins.Ourmodel protein recapitulates the aggregation features observedwith the clinical proteins and
allows structural characterization. With the use of NMR spectroscopy and a range of biophysical techniques, we demonstrate that
polyQ expansion into the pathological range has no effect on the structure, dynamics, and stability of a domain adjacent to the
polyQ tract. To explore the clinical signiﬁcance of repeat location, we engineered a variant of the model protein with a polyQ tract
within the domain, a location that does not mimic physiological context, demonstrating signiﬁcant destabilization and structural
perturbation. These different effects highlight the importance of repeat location. We conclude that protein misfolding within the
polyQ tract itself is the driving force behind the key characteristics of polyQ disease, and that structural perturbation of ﬂanking
domains is not required.
INTRODUCTION
Protein aggregation is a hallmark of a number of neurodegen-
erative diseases, including Alzheimer’s disease, Parkinson’s
disease, prion diseases, and the polyglutamine (polyQ) dis-
eases (1–3). A common feature of all of these diseases is the
formation of amyloid-like ﬁbrils with a common b-sheet rich
core (4–6). A signiﬁcant challenge is to determine the struc-
tural changes that occur during the formation of ﬁbrillar ag-
gregates, which remain unclear for many of the proteins
linked with misfolding and disease.
Nine inherited, late-onset polyQ disorders have been
identiﬁed, including Huntington’s disease (HD) and a num-
ber of spinocerebellar ataxias. The disease-linked mutation is
the expansion of a polyQ tract beyond a context-speciﬁc
threshold, which in the case of HD is ;37 glutamines. The
presence of an expanded polyQ tract leads to the deposition
of neuronal inclusions, cell death, and neurodegeneration.
The polyQ region is fundamental to disease, and although
there are many speciﬁc pathological and molecular pheno-
types, the ability of proteins with a pathological-length polyQ
tract to form ﬁbrillar aggregates is the common feature of
these nine diseases (5,7).
Aggregation studies of polyQ peptides and polyQ-con-
taining proteins suggest that the aggregation nucleus is a
monomer; therefore, determining the nature of the repeat
length-dependent conformational changes within the mono-
meric proteins is central to understanding the pathogenic
mechanism. Wetzel and colleagues (4) demonstrated that the
driving force for the aggregation of isolated polyQ peptides is
a random coil to b-sheet conformational conversion. Peptide
studies have provided key information regarding the isolated
polyQ tract; however, there is evidence to suggest that pro-
tein context has an important role in polyQ-derived patho-
genesis. Previous studies have shown that the composition of
the polyQ ﬂanking domains affects the solubility and toxicity
of pathological-length polyQ proteins (8–11). Recent ﬁnd-
ings indicating that proteins with expanded polyQ tracts have
mechanistic perturbations, and that aggregates may be
comprised of proteolytically cleaved fragments of polyQ-
containing proteins suggest that structural and/or dynamic
changes outside of the polyQ domain may be a common
consequence of repeat expansion (12–15). Indeed, Perutz
(16) hypothesized that proteins with pathological-length
polyQ tracts would be destabilized and hence the structure
and dynamics of the ﬂanking domains would be altered. The
native-state destabilization hypothesis has been investigated
with the use of ataxin-3 (17,18), a CRABP1-Htt exon1 fusion
(19), and a myoglobin-polyQ model protein (20). These
studies were hindered by several factors. The N-terminal
Josephin domain of ataxin-3 aggregates independently of
polyQ expansion (21,22). Htt exon 1 contains a C-terminal
oligoproline motif, and there is evidence that this modulates
the conformational properties of the polyQ repeat (23). In the
myoglobin-polyQ study, Tanaka et al. (20) inserted the polyQ
tract in a loop within the myglobin domain; however, within
the disease-associated proteins the tracts are found either
N- or C-terminal to other protein domains (24). Although it is
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clear that conformational changes in the polyQ tract due to
expansion lead to aggregation, one unresolved question is,
Does polyQ expansion lead to a change in the structure and
dynamics of surrounding domains? This is an important issue
in terms of therapeutic approaches because it would be far
easier to target and stabilize the folded domains surrounding
the polyQ tract than the polyQ region itself.
Here we present the ﬁrst, to our knowledge, structural
characterization of a domain fused to polyQ tracts of different
lengths. We report that the stability, structure, and dynamics
of the ﬂanking domain do not change when the polyQ tract
expands into the pathological range, and hence conclude that
it is the intrinsic propensity of the polyQ domain to adopt a
b-sheet structure that drives aggregation, a mechanism con-
sistent with polyQ peptide aggregation. Furthermore, we
show signiﬁcant structural perturbation when the polyQ tract
is engineered within a domain, which suggests that repeat
tract location determines the misfolding pathway, and there-
fore the choice of location is essential in the design of model
proteins. These location-dependent effects point toward the
clinical signiﬁcance of discrete repeat domains.
MATERIALS AND METHODS
Protein expression and puriﬁcation
The amino acid sequence of the B domain of Staphylococcus aureus Protein
A was codon-optimized and the gene was synthesized by TOP Gene Tech-
nologies (Quebec, Canada) and inserted into our pLIC-His construct for
expression (25). A construct with 5 C-terminal CAG repeats was also syn-
thesized (SpA-cQ5). To create the intradomain polyQ mutants, a comple-
mentary primer pair was designed to introduce ﬁve CAG repeats between
proline 39 and serine 40 of SpA using site-directed mutagenesis. Based on
the method of Peters and Ross (26), a method to incrementally amplify the
number of CAG repeats was devised that allowed the construction of C-ter-
minal fusion proteins with polyQ repeat lengths ranging from 5 to 52 glu-
tamines and intradomain polyQ variants with 9 and 25 glutamines inserted
between helices 2 and 3 of SpA.
Unlabeled SpA-polyQ fusion proteins were expressed in BL21(DE3)
cells by autoinduction (27). Labeled proteins for NMR uniformly enriched
with either 15N only or 15N/13C were expressed according to the protocol of
Marley et al. (28). Proteins were puriﬁed with the use of a two-step chro-
matography procedure and the Akta Express protein puriﬁcation system. A
nickel chelating chromatographic step was performed with the use of a 1 mL
HisTrap (GE Healthcare, Uppsala, Sweden) column according to the man-
ufacturer’s instructions. Proteins were further puriﬁed by gel ﬁltration
chromatography with a Superdex 75 16/60 or Superdex 200 16/60 column
(Pharmacia). Proteins were eluted and stored in the gel ﬁltration buffer (20
mM sodium acetate (pH 5.0), 100 mM NaCl, 10% (w/v) glycerol). Protein
concentration was determined by measuring the Abs280 of protein samples
unfolded with guanidine thiocyanate. The purity of proteins was analyzed by
means of 12% Tris-tricine sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE).
Size exclusion chromatography
Size exclusion chromatography (SEC) of SpA-polyQ proteins was per-
formed on an Akta-FPLC equipped with a Superdex 75 10/300 GL gel ﬁl-
tration column (Pharmacia). The column was precalibrated with proteins of
known molecular mass. SpA-polyQ samples at a concentration of 50 mM
were applied to the column, and UV absorption at 280 nm was monitored as
the proteins were eluted in 20 mM sodium acetate (pH 5.0), 100 mM NaCl,
2 mM phenylmethylsulphonyl ﬂuoride (PMSF), 10% (w/v) glycerol at a
constant ﬂow rate of 0.5 mL/min.
Circular dichroism
Circular dichroism (CD) spectra were measured on a Jasco-810 spectropo-
larimeter at 25C by means of a cuvette with a pathlength of 0.01 cm and
protein concentration of 30 mM. Spectra were recorded from 190 to 260 nm
with a scan speed of 50 nm/min. The spectra were analyzed by deconvolution
with the K2D algorithm as provided by the DICHROWEB online facility (29).
Protein aggregation time-course assays
SpA-polyQ proteins were incubated at a concentration of 20 mM in 20 mM
sodium acetate (pH 5.0), 100 mM NaCl, 2 mM PMSF, 10% (w/v) glycerol.
Reactions were performed at 37C without shaking and in airtight containers
to eliminate evaporation.
To monitor aggregation with the use of ThioﬂavinT (ThT), reactions were
performed in 384-well, clear-bottom plates in the presence of 20 mM ThT,
and ﬂuorescence emission intensity at 490 nmwas recorded (lex¼ 450) and
measured on a BMG Laboratories FLUOstar Optima ﬂuorescence plate
reader. Protein concentrations, buffering solutions, and additives were the
same as described above. Reactions were carried out at 37C, without
shaking, and the top of the plate was sealed to prevent evaporation.
PolyQ aggregation inhibition assays were performed with the QBP1
peptide. QBP1 peptide was purchased from AusPep with the same sequence
as described previously (30). The peptide was dissolved in 50%Me2SO/50%
(20 mM sodium acetate (pH 5.0), 100 mM NaCl, 10% (w/v) glycerol) and
incubated with SpA-polyQ aggregation assays (as above) at a ﬁnal con-
centration of 120 mM. Control assays with identical ﬁnal Me2SO concen-
trations were performed and showed no signiﬁcant effect of Me2SO addition.
Membrane ﬁlter trap assay
This assay was carried out with minor modiﬁcations to the previously de-
scribed protocol (31). A 10 mL aliquot of protein 20 mMwas removed from
the aggregation time-course incubations and diluted at a ratio of 1:1 in a
solution of 4% SDS (w/v) and 100 mM dithiothreitol. The samples were
heated for 5min at 100C before being diluted to 150mLwith 2% (w/v) SDS.
The samples were ﬁltered through a cellulose acetate membrane (Schleicher
and Schuell, 0.2 mm) using a Bio-Rad Bio-Dot SF microﬁltration unit. After
application, the membrane was washed twice by ﬁltering through 150 mL of
0.1% (w/v) SDS. Immunoblot analysis was performed using a primary anti-
His antibody (Serotec).
Transmission electron microscopy
Transmission electron microscopy (TEM) images were obtained using an
Hitachi H7500 transmission electron microscope. The acceleration voltage
was 80 kV. The samples were adsorbed onto a carbon-coated grid and stained
with 1% (w/v) uranyl acetate.
Thermal and guanidine denaturation
Protein at a concentration of 20 mM was denatured as the temperature was
increased from 40C to 90C at a rate of 1C/min. Samples in the presence or
absence of 1 M GuHCl were in a thermostated cuvette with a pathlength of
0.1 cm, and the CD signal at 222 nm was measured.
For chemical denaturation experiments, guanidine hydrochloride (GuHCl)
was prepared in 20 mM sodium acetate (pH 5.0), 100 mM NaCl, 10% (w/v)
glycerol. Equilibrium unfolding titrations were set up with GuHCl ranging
from 0 to 6M, with a protein concentration of 20mM. Proteins were incubated
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in GuHCl solutions at room temperature for 30 min, and the CD signal at 222
nm (CD222) was recorded. To determine reversibility, proteins unfolded in 6M
GuHCl were titrated back into Buffer A and CD222 was recorded.
NMR experiments and SpA-cQ5
structure determination
Samples for NMR analysis were prepared to a concentration of 1 mM and
150 mM of SpA-cQ5 and SpA-cQ52, respectively, in 20 mM sodium acetate
(pH 5.0), 100 mM NaCl, 10% (w/v) glycerol in 90% H2O: 10%
2H2O. All
experiments were recorded on a Varian Unity 600 MHz spectrometer
equipped with a triple resonance cold probe with actively shielded gradients
at a temperature of 298 K. For the comparison of SpA-cQ5 and SpA-cQ52,
10% (w/v) glycerol was added to both samples to improve the SpA-cQ52
sample stability and to conﬁrm that there was no signiﬁcant effect on the
SpA-cQ5 spectra.
Standard triple resonance experiments were recorded to obtain assign-
ments for SpA-cQ5 (32). Two- and three-dimensional nuclear Overhauser
enhancement spectroscopy (NOESY) experiments were recorded for mea-
surement of interproton distances (33).
Data were processed with the use of NMRPipe (34) and analyzed with the
software SPARKY (Goddard and Kneller, University of California, San
Francisco, CA). Initial structures were calculated in Cyana-2.1 by means of
automated NOE assignment (35). Backbone f/c angle restraints were cal-
culated based on chemical shifts for Ca, Cb, Ha, HN, and C9 nuclei with the
software TALOS (36). The ﬁnal structures were reﬁned with Xplor-NIH
(37). Hydrogen-bond restraints were added for amide protons with measured
slow exchange in CLEANEX-PM (38) experiments and for which a hy-
drogen bond acceptor could be identiﬁed clearly in the initial structure en-
sembles. The ensemble of 29 structures had no NOE violations . 0.3 A˚ or
dihedral violations . 5 and good overall geometry as determined by
Whatcheck and Procheck-NMR, and was deposited in the Protein Data Bank
(PDB id: 2JWD).
RESULTS
PolyQ proteins with repeat lengths of $35 form
ﬁbrillar aggregates
We constructed a family of proteins containing variable-
length polyQ regions attached to the C terminus of the Pro-
tein A B domain (Y15W mutant) from Staphylococcus
aureus (SpA) (39–41). The length of the polyQ tract within
the polyQ protein increases incrementally, from ﬁve to 52
glutamines (Fig. 1 a). Size-exclusion chromatography dem-
onstrated that all of the proteins were entirely monomeric
(Fig. 1 b). The elution volume of the protein increased line-
arly with the number of glutamines, indicating that there is no
thermodynamically favorable conformational change within
the monomeric proteins with increasing polyQ length. This
observation is consistent with previous data indicating that,
regardless of repeat length, polyQ tracts exist in a random coil
in solution (42). This was further conﬁrmed by far-UV CD
analyses of the polyQ proteins (Fig. 1 c). The presence of the
polyQ tract causes little change in the SpA spectra, with
spectral deconvolution, indicating that the polyQ is random
coil in structure, with a proportional decrease in a-helical
content from 79% in SpA-Q0 to 48% in SpA-cQ52, and a
concomitant increase in fraction of random coil from 20% in
SpA-Q0 to 40% in SpA-cQ52.
Only SpA-polyQ proteins with polyQ tracts of 35 or
greater formed ThT-reactive aggregates with a rate depen-
dent on the repeat length (Fig. 2 a). The duration of the lag
phase decreased exponentially as a function of polyQ length
as the number of glutamines increased from 35 to 52 repeats.
This is indicated by the change in the midpoint of the ThT
curves, going from ;270 h for SpA-cQ35 and decreasing
exponentially to plateau at;10–15 h for proteins with 48–52
glutamines (Fig. 2 a, inset). Analysis of the kinetics of ag-
gregation also demonstrated both time and concentration
dependence, consistent with the nucleation-polymerization
aggregation model proposed for polyQ aggregation (43)
(data not shown). In addition, the aggregates were found to be
resistant to solubilization by SDS and their formation could
be inhibited by the QBP1 peptide (30,31) (Fig. 2 b). Mor-
phological analysis of each protein revealed that regardless of
polyQ length, all form similar amyloid-like ﬁbrillar struc-
FIGURE 1 SpA-polyQ proteins are monomeric and the polyQ region is
unstructured. (a) Puriﬁed SpA-polyQ fusion proteins were analyzed by 12%
(w/v) SDS-PAGE. (b) SpA-polyQ fusion proteins were analyzed by SEC
using a Superdex 75 column. The elution proﬁles of SpA-Q0, SpA-cQ5,
SpA-cQ20, SpA-cQ35, and SpA-cQ52 are shown. (Inset) The elution
volumes of all 12 proteins are plotted against the number of glutamines
on the inset graph, showing a linear relationship. (c) Far-UV CD spectra of
SpA-polyQ proteins. The spectra of SpA-Q0, SpA-cQ5, SpA-cQ20, SpA-
cQ35, and SpA-cQ52 are shown. There is increasing random coil content
with expansion of the polyQ region.
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tures, which are unbranched and range from 7 to 15 nm in
diameter (Fig. 2, c–e). There was no observation of ﬁbrils for
SpA-cQ31 or variants with shorter repeat lengths. Taken
together, the aggregation data suggest that the expanded
SpA-polyQ proteins form amyloid-like ﬁbrils with a disease
threshold, structure, and kinetic mechanism similar to those
of the disease-causing proteins.
Thermodynamic stability is not linked to
polyQ expansion
The increased aggregation propensity of SpA-polyQ variants
with $35 glutamines, combined with evidence that the
composition of ﬂanking regions inﬂuences aggregation and
toxicity, suggests that mutant polyQ expansions may affect
the conformation of the surrounding domains. To investigate
this, we performed thermal and guanidine (GuHCl) equilib-
rium un/folding experiments on the 12 SpA-polyQ proteins.
Of interest, we found that all 12 proteins displayed equivalent
thermal and GuHCl-induced unfolding proﬁles, with mid-
points for the unfolding transitions of ;69C and 4 M, re-
spectively (Fig. 3, a and b, Table 1). Guanidine-induced
unfolding transitions were found to be two-state and fully
reversible. DG values were similar for all 12 proteins (0–52
Qs), ranging from 6 to 7 kcal/mol, indicating that polyQ
expansion had no effect on protein stability. Many proteins,
under conditions that cause partial unfolding (such as low
denaturant concentrations in which hydrophobic interactions
are disrupted), are prone to spontaneous aggregation. To
further conﬁrm that SpA-polyQ protein samples in GuHCl-
induced folding titrations remained monomeric, ThT and
SEC analyses of samples in the presence of 0–6 M GuHCl
were performed, and the results indicated that there were no
aggregates present (data not shown). The fact that the pres-
ence of guanidine does not induce aggregation of proteins
with an expanded polyQ tract is consistent with a model in
which aggregation is entirely driven by the polyQ region.
The structure and dynamics of the ﬂanking
domain are unaffected by polyQ expansion
The un/folding data suggest that expansion of the polyQ re-
gion does not affect the conformation of SpA; however, this
is a global stability measure and offers no insight at the amino
FIGURE 2 Expanded PolyQ proteins form typical ﬁbrils. (a) ThT analysis of aggregation formation for proteins with repeat lengths $35. Proteins with
repeat lengths below 35 did not aggregate over the 500 h timespan analyzed. Curves shown are single exponential ﬁts of data sets. (Inset) The midpoints of the
ThT traces plotted as a function of repeat length. (b) Analysis of the SDS stability of endpoint aggregates in the presence (top panel) and absence (bottom panel)
of QBP1. (c–e) TEM analysis SpA-cQ35 (c), SpA-cQ48 (d), and SpA-cQ52 (e). Scale bars are 200 nm.
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acid level. We utilized NMR to speciﬁcally assess the impact
of polyQ expansion on the structure of the SpA domain to
determine whether there might be local conformational
changes induced by polyQ expansion. The NMR experi-
ments also provided crucial insight into the dynamic prop-
erties of the SpA domain in the different proteins. Such
information is invaluable for determining whether a patho-
logical-length polyQ tract alters the conformational hetero-
geneity of the native ensemble. We determined the NMR
structure of SpA-cQ5, which remained essentially unchanged
from that of the previously reported NMR structure for the
SpA domain (40) (Fig. 4, a and b; Table 2). To identify
structural changes caused by polyQ expansion into the
pathological range, we performed 1H-15N-HSQC experi-
FIGURE 3 PolyQ expansion does not affect thermal or GuHCl-induced
denaturation proﬁles. (a) All polyQ proteins showed similar thermal
unfolding proﬁles. The change in CD signal at 222 nm was monitored as
proteins were heated from 40C to 90C in the presence of 1 M GuHCl. (b)
All polyQ proteins showed similar unfolding proﬁles when unfolded with
GuHCl. SpA-Q0, SpA-cQ5, SpA-cQ20, SpA-cQ35, and SpA-cQ52 are
shown as representative traces and thermal and chemical denaturation
proﬁles of all proteins overlayed (Table 1).
TABLE 1 Equilibrium stability of C-terminal
SpA-polyQ proteins
Tm (C)* Dm (M)y DG (kcal/mol)z
SpA-Q0 69.0 6 0.4 4.1 6.5 6 0.2
SpA-cQ5 69.3 6 0.5 4.2 6.8 6 0.3
SpA-cQ9 69.3 6 0.3 4.1 6.6 6 0.3
SpA-cQ13 68.8 6 0.3 4.1 6.5 6 0.5
SpA-cQ20 68.7 6 0.4 4.1 6.6 6 0.2
SpA-cQ24 69.4 6 0.3 4.1 6.5 6 0.5
SpA-cQ31 70.0 6 0.4 3.9 6.2 6 0.3
SpA-cQ35 69.4 6 0.5 4.2 6.7 6 0.2
SpA-cQ40 68.7 6 0.5 4.0 6.4 6 0.2
SpA-cQ45 68.8 6 0.4 4.1 6.5 6 0.5
SpA-cQ48 69.4 6 0.4 4.1 6.5 6 0.5
SpA-cQ52 69.3 6 0.5 4.2 6.7 6 0.2
*Midpoint of the thermal denaturation curves determined by measuring the
change in CD signal at 222 nm in the presence of 1 M GuHCl.
yMidpoints of the GuHCl-denaturation curves determined using the equa-
tion for two-state unfolding.
zDG was determined by analysis of the GuHCl-denaturation curves, with a
shared equilibrium m value of 1.6 kcal/mol/M.
FIGURE 4 Structure of the ﬂanking domain. (a) Backbone atom (N, Ca,
C9) trace of the ensemble of 29 structures of SpA-cQ5 and 90 rotation
around the y axis. (b) Backbone atom superposition of the ﬁve structures
with the lowest energy from our ensemble of SpA-cQ5 (green) with the ﬁrst
ﬁve structures from the published 1SS1.pdb NMR ensemble for SpA
(yellow). (c) Overlays of 1H-15N -HSQC spectra for SpA-cQ5 (magenta)
and SpA-cQ52 (cyan) recorded at 600 MHz and 25C.
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ments on SpA-cQ52. A comparison of the 1H and 15N
chemical shifts for residues in the SpA domain of SpA-cQ5
and SpA-cQ52 revealed no signiﬁcant chemical-shift per-
turbations. This suggests that the structure of SpA is not
perturbed even when fused to 52 glutamines, as demonstrated
by the overlaid 1H-15N-HSQC spectra (Fig. 4 c). The re-
dundant glutamine chemical shifts in the SpA-cQ52 spectra
suggest that the polyQ tail exists in a random coil confor-
mation, consistent with our far-UV CD data. To retard ag-
gregation of the SpA-cQ52 sample, an;7-fold lower protein
concentration was used as compared to the SpA-cQ5 sample;
therefore, a direct comparison of the peak intensities between
the spectra is uninformative. Analysis of the peaks across the
individual spectra, however, reveals that in each data set the
relative intensities of the cross peaks remain similar. That is,
none of the cross peaks in the 1H-15N HSQC data of SpA-
cQ52 are either selectively broadened or changed in intensity
compared to the spectrum of SpA-cQ5. These data suggest
that polyQ expansion into the pathological range does not
result in perturbation of the structure of the ﬂanking domain,
and that the SpA-cQ5 and SpA-cQ52 proteins are similar in
terms of their dynamics.
A polyQ tract disrupts tertiary interactions when
located within the domain
To explore the signiﬁcance of repeat location, we engineered
a variant of the SpA-polyQ model protein with a polyQ tract
within a ﬂexible loop of SpA to observe the effects of an
intradomain polyQ repeat on host domain stability and
structure (in a nonphysiological location). We engineered
insertion mutants with the polyQ tract placed in the ﬂexible
loop between helices 2 and 3 of SpA, the insertion site in-
dicated by the arrow in Fig. 6 c. Poor protein expression
limited analyses to variants with repeat lengths below the path-
ological range, and as a result we did not observe aggregation
of these variants; however, we did observe destabilization of
variants with Q9 and Q25 inserts (denoted SpA-iQ9 and
SpA-iQ25, respectively). As compared to wild-type SpA
(SpA-Q0), the SpA-iQ9 variant was signiﬁcantly destabi-
lized by ;4.7 kcal/mol, and SpA-iQ25 was further destabi-
lized (Fig. 5 a, Table 3). Decreased thermal stability was also
observed with shifts in the thermal denaturation midpoints
with increasing repeat length (Fig. 5 b, Table 3).
We assessed the effect of the intradomain Q9 and Q25 inserts
on the structure of SpA by CD and NMR. CD analyses dem-
onstrated that the SpA-iQ9 and SpA-iQ25 variants retain their
a-helical secondary structure (Fig. 6 a). The polyQ insertions,
however, affect the tertiary structure of SpA, as demonstrated by
the high-ﬁeldmethyl regions in the 1D 1HNMRspectra of SpA,
SpA-cQ5, and SpA-iQ9 (Fig. 6 b). The spectrum of SpA con-
tains several resonances for methyl groups with chemical shifts
of,0.5 ppm, as would be expected in a folded protein domain.
The highest ﬁeld resonances are observed for Ile17, Leu18,
Leu20, and Ala49. The location of these methyl groups in the
tertiary structure of SpA is highlighted in Fig. 6 c. The methyls
FIGURE 5 Intradomain polyQ tract affects the stability of SpA. (a)
Thermal denaturation of SpA-Q0, SpA-iQ9, and SpA-iQ25. The change
in CD signal was monitored as proteins were unfolded from 20C to 90C.
(b) GuHCl unfolding of SpA-Q0, SpA-iQ9, and SpA-iQ25. SpA-iQ9 and
SpA-iQ25 unfold in lower concentrations of GuHCl relative to SpA-Q0.
TABLE 2 NMR and reﬁnement statistics for 29 SpA-cQ5
model structures
NMR distance and dihedral constraints
Distance constraints
Total NOE
Interresidue 657
Short-range (jijj ¼ 1) 237
Medium-range (jijj , 4) 253
Long-range (jijj . 3) 97
Total dihedral angle restraints 77
f 37
c 38
H-bond distance restraints 14
Structure statistics
Violations (mean and SD)
Distance constraints (A˚) 0.0325 6 0.0041
Dihedral angle constraints () 0.3187 6 0.1571
Deviations from idealized geometry
Bond lengths (A˚) 0.0038 6 0.00018
Bond angles () 0.7338 6 0.0265
Impropers () 0.6903 6 0.0354
Lennard-Jones energy (kcal mol1)* 258.91 6 7.82
Root mean-square deviation to the
mean structure (A˚)
Backbone 0.387 6 0.124
Heavy 0.878 6 0.158
Pairwise root mean-square deviation was calculated among 29 reﬁned
structures.
*Lennard-Jones energy values from CNS using protein par parameters from
the Xplor-NIH distribution.
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of Ile17, Leu20, and Ala49 are clustered in the interior of the SpA
fold. These resonances are unperturbed upon addition of glu-
tamine extensions at the C terminus of SpA. However, upon
insertion of glutamine residueswithin the SpAdomain, there are
notable changes in the spectrum. The high-ﬁeld methyl reso-
nances are lost and collapse to the 0.8–1.0 ppm region. The
change in the 1H NMR spectrum of SpA-iQ9 is consistent with
a destabilization of the tertiary structure of the protein upon
insertion of the glutamine repeats. Similar perturbations were
observed in the spectra of SpA-iQ25 (data not shown).
DISCUSSION
In all polyQ-related diseases, the length of the polyQ expan-
sion deﬁnes both the age of onset and disease duration. The
speciﬁc features of each disease, however, suggest that pro-
tein context plays a key role in modulating the formation of
neuronal aggregates, and this is supported by in vitro analyses
(8,11). In the disease proteins, the polyQ tract initially exists
as a ﬂexible solvent-exposed domain (24).We have replicated
this environment with polyQ regions fused to the C terminus
of ana-helical model domain, SpA. The relationship between
polyQ repeat length and aggregation seen here recapitulates
the exponential association between repeat length and age of
HD onset, and the in vitro aggregation rates of Htt exon1
proteins (5,7,44). Further, only SpA-polyQ proteinswith$35
glutamines formed SDS-stable and morphologically observ-
able ﬁbrils. Our system is also supported by the observation
that a repeat length of at least 35 glutamines is required for
aggregation initiation, similar to the threshold seen in disease.
Taken together, these observations suggest that the SpA do-
main chosen as a model in this study behaves similarly to the
ﬂanking domains in the disease proteins, validating the rele-
vance of our stability and structural data.
Here we examined the hypothesis proposed by Perutz (16),
that polyQ expansion causes destabilization and conforma-
tional rearrangements of ﬂanking domains. We ﬁnd that,
regardless of repeat length, the C-terminal SpA-polyQ fusion
proteins have equivalent thermodynamic stability. These un/
folding experiments provide information on the global free
energy change, with contributions from the polyQ region and
ﬂanking SpA domain. It could be anticipated that the local
stability of the polyQ region may change with increasing
repeat length. The increased proportion of unstructured
conformation, as identiﬁed by our CD analyses, would
increase the main chain entropy, and unless this is offset by
an equivalent increase in solvent entropy, this effect would be
reﬂected by a lowered free energy of the native state. These
changes could therefore mask the detection of small changes
in free energy contributed by structural alterations of the
ﬂanking domain.
TABLE 3 Equilibrium stability of intradomain
SpA-polyQ proteins
Tm (C)* Dm (M)y DG (kcal/mol)z
SpA-Q0 —§ 4.1 6.5 6 0.2
SpA-iQ9 46.6 6 1 1.5 1.8 6 0.3
SpA-iQ25 38.9 6 1 —{ —{
*Midpoints of thermal denaturation were determined by measuring the
change in CD signal at 222 nm.
yMidpoints of the GuHCl-denaturation curves determined using the equa-
tion for two-state unfolding.
zDG was determined by analysis of the GuHCl-denaturation curves, with a
shared equilibrium m value of 1.6 kcal/mol/M.
§Tm for SpA-Q0 could not be determined due to lack of post-transition
baseline.
{Dm and DG could not be determined for SpA-iQ25 as data could not be
ﬁt to two-state unfolding equation due to absence of pretransition baseline.
FIGURE 6 Intradomain polyQ repeat structurally perturbs SpA. (a) CD
spectra of SpA-Q0, SpA-iQ9, and SpA-iQ25 showing that a-helical SpA
secondary structure is retained in SpA-iQ9 and SpA-iQ25 variants. (b) The
high-ﬁeld region of the 1H-NMR spectra of SpA-Q0, SpA-cQ5, and SpA-
iQ9, respectively. (c) Cartoon representation of the structure of SpA
demonstrating the location of the methyl groups that resonate at the highest
ﬁeld in the 1H-NMR spectrum.
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We used NMR to more speciﬁcally determine the effect of
polyQ expansion on the structure of the SpA domain. The
1H-15N-HSQC spectra for SpA-cQ5 and SpA-cQ52 demon-
strate that the SpA domain, even when fused to a patholog-
ical-length polyQ region, remains structurally equivalent to
SpA alone. Further, the comparable peak intensities across
the SpA-cQ5 and SpA-cQ52 spectra suggest that there is a
similar degree of conformational heterogeneity for both
proteins, supporting the idea of an equivalent equilibrium
between the native and unfolded states.
An analysis of all repeat-containing proteins by Faux et al.
(24) showed that 73% of all homopeptide repeats are located
N9 or C9 to a structured domain. Of the nine disease-related
polyQ proteins, at least seven have polyQ tracts located in
ﬂexible, unstructured regions N- or C-terminal to a folded
domain. Given the preference of poly amino acid tracts to be
located external to a folded domain, we assessed the signif-
icance of this in a polyQ protein by analyzing a protein with
an intradomain polyQ tract. We observed signiﬁcant desta-
bilization of the protein and perturbation of the tertiary
structure even with a short polyQ tract (SpA-iQ9). The effect
of the intradomain polyQ insertion in this case is similar to
other model polyQ proteins in which a polyQ tract was in-
serted within a domain (20,45).
The location-dependent effects of the polyQ tract on the
native fold suggest that an expanded repeat tract can induce
alternative misfolding pathways. Our data for the C-terminal
polyQ proteins are consistent with, and build upon, the model
for polyQ peptides in which conformational changes intrinsic
to the polyQ segment are sufﬁcient for aggregation to pro-
ceed. This contrasts with the signiﬁcant perturbation we saw
when the polyQ tract was placed within a ﬂexible loop of
SpA, suggesting that intrinsic polyQ conversion and native-
state destabilization can be coincident misfolding pathways.
In light of the ﬁnding that polyQ expansion within Htt
exon1 does destabilize the adjacently fused b-barrel protein
CRABP1, our data add complexity to the picture of polyQ-
induced misfolding. SpA and CRABP1 differ in native-state
stability and topological arrangements, offering alternative
models for the conformational properties of the polyQ
ﬂanking domains. The ultimate goal, which currently is im-
peded by the size and solubility of the polyQ disease proteins,
is to determine the properties of their ﬂanking domains. This
would be of signiﬁcant interest because the varied results of
model polyQ proteins suggest that location and context are
key determinants of the perturbing inﬂuence of polyQ ex-
pansion.
Our NMR data clearly show that polyQ expansion does not
affect the stability of a folded ﬂanking domain when fused at
the C terminus, a result in contrast to another model protein
(19). To our knowledge, this is the ﬁrst study to provide direct
structural information about a ﬂanking domain attached to a
polyQ tract. Our result does not preclude a perturbing inﬂu-
ence of polyQ expansion on surrounding polypeptide re-
gions, but rather suggests that this relationship is complex,
and this is supported by our data showing compromised
stability and structure of an intradomain polyQ chimera. The
result presented here differs from the classical misfolding
model proposed for amyloid formation, in which destabili-
zation of the native state leads to ﬁbril formation in a num-
ber of diseases (46–48). Alteration of native-state stability,
however, is not a necessary mechanism underlying amyloid
formation for a number of other disease-causing proteins,
including the prion protein, in which disease-associated
mutations do not necessarily alter thermodynamic properties
(49,50). In the greater context of amyloid-deposition dis-
eases, the result presented here further highlights the variable
pathways along which proteins can aggregate to form uni-
form amyloid-like aggregates.
S.P.B. is a senior research fellow of the National Health and Medical
Research Council (NHMRC), and the work was supported by both the
Australian Research Council and NHMRC of Australia.
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